What Researchers Did
Doctors compared a hyperbaric oxygen treatment called alternobaric oxygen therapy with standard medication in patients with Meniere's disease, a condition that causes vertigo and hearing problems.
What They Found
A controlled clinical study of 20 patients treated with alternobaric oxygen therapy (ABOT) versus 18 patients treated with glycerol and betahistine found no statistically significant difference between the two groups after the first 15 days of treatment, with both groups followed for up to four years. Over the longer four-year follow-up, the abstract reports that ABOT-treated patients had significantly fewer episodes of vertigo and improved outcomes compared to the control group, though the abstract does not give the specific numbers for this later comparison. Hearing thresholds and tinnitus frequency were also tracked in both groups using standard hearing and equilibrium criteria.
What This Means for Canadian Patients
For people with Meniere's disease, this study suggests alternobaric oxygen therapy may reduce vertigo episodes over several years of treatment, though it showed no clear early advantage over standard medication in the first 15 days. The treatment protocol involved repeated sessions over multiple years, which is a significant time commitment patients should discuss with their doctor.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract does not report specific numerical results for its four-year follow-up comparison, and with only 20 and 18 patients in the two groups, the small sample size limits how confidently these findings can be generalized.